HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. LENZ | 0.00 |
HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:
LENZ) with a Buy and maintains $38 price target.
